The role of tirofiban in the management of coronary artery disease

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 2, 2008, Pages 138-146

  Winter, Julian P ^a   Juergens, Craig P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Acute coronary syndromes; Glycoprotein IIb IIIa antagonists; Percutaneous coronary intervention; Platelets; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TYROSINE;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MONOTHERAPY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACODYNAMICS; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; COST BENEFIT ANALYSIS; DRUG DESIGN; ECONOMICS; METHODOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG DESIGN; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TYROSINE;

EID: 48249113738     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908784533748     Document Type: Article

References (48)

1. Lefkovits, J.; Plow, E.F.; Topol, E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med., 1995, 332, 1553-1559.
2. Quinn, M.J.; Byzova, T.V.; Qin, J.; Topol, E.J.; Plow, E.F. Integrin alphaIIbbeta3 and its antagonism. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 945-952.
3. Coller, B.S.; Peerschke, E.I.; Scudder, L.E.; Sullivan, C.A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J. Clin. Invest, 1983, 72, 325-338.
4. Dasgupta, H.; Blankenship, J.C.; Wood, G.C.; Frey, C.M.; Demko, S.L.; Menapace, F.J. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am. Heart J., 2000, 140, 206-211.
5. Topol, E.J.; Byzova, T. V.; Plow, E.F. Platelet GPIIb-IIIa blockers. Lancet, 1999, 353, 227-231.
6. Effects of platelet glycoprotein II/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation, 1997,96, 1445-1453.
7. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by nstab le Signs and Symptoms (PRISM-PL S) Study Investigators. N. Engl. J. Med., 1998, 338, 1488-1497.
8. Lee, D.P.; Herity, N.A.; Hiatt, B.L; Fearon, W.F.; Rezaee, M.; Carter, A.J.; Huston, M.; Schreiber, D.; DiBattiste, P.M.; Yeung, A.C. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation, 2003, 107, 1497-1501.
9. van't Hof, A.W.; Ernst, N.; de Boer, M.J.; de Winter, R.; Boersma, E.; Bunt, T.; Petronio, S.; Marcel Gosselink, A.T.; Jap, W.; Hollak, F.; Hoorntje, J.C.; Suryapranata, H.; Dambrink, J.H.; Zijlstra, F.; On-TIME study group. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur. Heart J., 2004, 25, 837-846.
10. Batchelor, W.B.; Tolleson, T.R.; Huang, Y.; Larsen, R.L.; Mantell, R.M.; Dillard, P.; Davidian, M.; Zhang, D.; Cantor, W.J.; Sketch, M.H., Jr.; Ohman, E.M.; Zidar, J.P.; Gretler, D.; DiBattiste, P.M.; Tcheng, J.E.; Califf, R.M.; Harrington, R.A. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002, 106, 1470-1476.
11. Topol, E.J.; Moliterno, D.J.; Herrmann, H.C.; Powers, E.R.; Grines, C.L.; Cohen, D.J.; Cohen, E.A.; Bertrand, M.; Neumann, F.J.; Stone, G.W.; DiBattiste, P.M.; Demopoulos, L. TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med., 2001, 344, 1888-1894.
12. Valgimigli, M.; Percoco, G.; Barbieri, D.; Ferrari, F.; Guardigli, G.; Parrinello, G.; Soukhomovskaia, O.; Ferrari, R. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J. Am. Coll. Cardiol., 2004,44, 14-19.
13. Gunasekara, A.P.; Walters, D.L.; Aroney, C.N. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention. Int. J. Cardiol., 2006, 109, 16-20.
14. Marguerie, G.A.; Plow, E.F.; Edgington, T.S. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J. Biol. Chem., 1979, 254, 5357-5363.
15. Ruggeri, Z.M.; Bader, R.; DeMarco, L. Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proct. Natl. Acad. Sci. USA, 1982, 79, 6038-6041.
16. Beacham, D.A.; Wise, R.J.; Turci, S.M.; Handin, R.I. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in von Willebrand factor by site-directed mutagenesis. J. Biol. Chem., 1992, 267, 3409-3415.
17. Cox, D.; Aoki, T.; Seki, J.; Motoyama, Y.; Yoshida, K. The pharmacology of the integrins. Med. Res. Rev., 1994, 14, 195-228.
18. Tam, S.H.; Sassoli, P.M.; Jordan, R.E.; Nakada, M.T. (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation, 1998, 98, 1085-1091.
19. Gowda, R.M.; Khan, I.A.; Vasavada, B.C.; Sacchi, T.J. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism. Am. J. Ther., 2004, 11, 302-307.
20. Kereiakes, D.J.; Kleiman, N.S.; Ambrose, J.; Cohen, M.; Rodriguez, S.; Palabrica, T.; Herrmann, H.C.; Sutton, J.M.; Weaver, W.D.; McKee, D.B.; Fitzpatrick, V.; Sax, F.L. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J. Am. Coll. Cardiol., 1996, 27, 536-542.
21. Schneider, D.J.; Baumann, P.Q.; Whitaker, D.A.; Sobel, B.E. Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen. J. Cardiovasc. Pharmacol., 2005, 46, 41-45.
22. Schneider, D.J.; Keating, F.K.; Baumann, P.Q.; Whitaker, D.A.; Sobel, B.E. Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus. Coron. Artery Dis., 2006, 17, 57-61.
23. Huber, W.; Hurst, J.; Schlatter, D.; Barner, R.; Hubscher, J.; Kouns, W.C.; Steiner, B. Determination of kinetic constants for the interaction between the platelet glycoprotein IIb-IIIa and fibrinogen by means of surface plasmon resonance. Eur. J. Biochem., 1995, 227, 647-656.
24. The EPISTENT Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N. Engl. J. Med., 1999, 341, 319-327.
25. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The P R S I T Trial Investigators. Platelet Glycoprotein IIb/IIIa in nstab le Angina: Receptor Suppression sing Integrilin Therapy. N. Engl. J. Med., 1998, 339, 436-443.
26. de Feyter, P.J.; van den, B.M.; Laarman, G.J.; van Domburg, R.; Serruys, P. W., Suryapranata, H. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up. Circulation, 1991, 83, 927-936.
27. Yang, E.H.; Gumina, R.J.; Lennon, R.J.; Holmes, D.R.; Rihal, C.S.; Singh, M. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J. Am. Coll. Cardiol., 2005, 46, 2004-2009.
28. Narins, C.R.; Hillegass, W.B.; Nelson, C.L.; Tcheng, J.E.; Harrington, R.A.; Phillips, H.R.;l Stack, R.S.; Califf, R.M. Relation between Activated Clotting Time during Angioplasty and Abrupt Closure. Circulation, 1996, 93, 667-671.
29. Lembo, N.J.; Black, A.J.; Roubin, G.S.; Wilentz, J.R.; Mufson, L.H.; Douglas, J.S.J.; King, S.B. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am. J. Cardiol., 1990, 65, 422-426.
30. Cannon, C.P.; Weintraub, W.S.; Demopoulos, L.A.; Vicari, R.; Frey, M.J.; Lakkis, N.; Neumann, F.J.; Robertson, D.H.; DeLucca, P.T.; DiBattiste, P.M.; Gibson, C.M.; Braunwald, E. TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) - TIMI 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban (TACTICS-TIMI 18. N. Engl. J. Med., 2001, 344, 1879-1887.
31. Juergens, C.P.; White, H.D.; Belardi, J.A.; Macaya, C.; Soler-Soler, J.; Meyer, B.J.; Levy, R.D.; Hunt, T.; Menten, J.; Herrmann, H.C.; Adgey, A.A.; Tarnesby, G. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clin. Ther., 2002, 24, 1332-1344.
32. The EPIC Investigators. se of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty. N. Engl. J. Med., 1994, 330, 956-961.
33. The EPILOG Investigators. Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularisation. N. Engl. J. Med., 1997, 336, 1689-1696.
34. Bonz, A.W.; Lengenfelder, B.; Strotmann, J.; Held, S.; Turschner, O.; Harre, K.; Wacker, C.; Waller, C.; Kochsiek, N.; Meesmann, M.; Neyses, L.; Schanzenbacher, P.; Ertl, G.; Voelker, W. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J. Am. Coll. Cardiol., 2002, 40, 662-668.
35. McKay, R.G.; Boden, W.E. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the P RS I I, PRISM, PRISM-PL S, TACTICS, and PARAGON Trials. Current inion in Cardiology, 2001, 16, 364-369.
36. Moliterno, D.J.; Yakubov, S.J.; DiBattiste, P.M.; Herrmann, H.C.; Stone, G.W.; Macaya, C.; Neumann, F.J.; Ardissino, D.; Bassand, J.P.; Borzi, L.; Yeung, A.C.; Harris, K.A.; Demopoulos, L.A., Topol, E.J. TARGET, I. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with atent placement: the TARGET follow-up study. Lancet, 2002, 360, 355-360.
37. Mukherjee, D.; Topol, E.J.; Bertrand, M.E.; Kristensen, S.D.; Herrmann, H.C.; Neumann, F.J., Yakubov, S.J., Bassand, J.P., McClure, R.R., Stone, G.W., Ardissino, D.; Moliterno, D.J. TARGET, I. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur. Heart J., 2005, 26, 2524-2528.
38. Weaver, W.D.; Simes, R.J.; Betriu, A.; Grines, C.L.; Zijlstra, F.; Garcia, E.; Grinfeld, L.; Gibbons, R.J.; Ribeiro, E.E.; DeWood, M.A.; Ribichini, F. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA, 1997, 278, 2093-2098.
39. Stone, G.W.; Cox, D.; Garcia, E.; Brodie, B.R.; Morice, M.C.; Griffin, J.; Mattos, L.; Lansky, A.J.; O'Neill, W.W.; Grines, C.L. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation, 2001, 104, 636-641.
40. De Luca, G.; Ernst, N.; van't Hof, A.W.; Ottervanger, J.P.; Hoorntje, J.C.; Dambrink, J.H.E.; Gosslink, A.T.M.; de Boer, M.J.; Suryapranata, H. Preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty. Am. Heart J., 2005, 150, 827-831.
41. Gold, H.K.; Garabedian, H.D.; Dinsmore, R.E.; Guerrero, L.J.; Cigarroa, J.E.; Palacios, I.F.; Leinbach, R.C. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation, 1997, 95, 1755-1759.
42. van den Merkhof, L.F.; Zijlstra, F.; Olsson, H.; Grip, L.; Vein, G.; Bar, F.W.; van den Brand, M.J.; Simoons, M.L.; Verheugt, F.W. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J. Am. Coll. Cardiol., 1999, 33, 1528-1532.
43. De Luca, G.; Suryapranata, H.; Stone, G.W.; Antoniucci, D.; Tcheng, J.E.; Neumann, F.J.; Van de, W.F.; Antman, E.M.; Topol, E.J. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA, 2005, 293, 1759-1765.
44. Bolognese, L.; Falsini, G.; Liistro, F.; Angioli, P.; Ducci, K.; Taddei, T.; Tarducci, R.; Cosmi, F.; Baldassarre, S.; Burali, A. Randomised comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The EVEREST trial. J. Am. Coll. Cardiol., 2006, 47, 522-528.
45. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet, 1997, 349, 1422-1428.
46. Merlini, P.A.; Rossi, M.; Menozzi, A.; Buratti, S.; Brennan, D.M.; Moliterno, D.J.; Topol, E.J.; Ardissino, D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation, 2004, 109, 2203-2206.
47. Szucs, T.D.; Meyer, B.J.; Kiowski, W. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PL S trial. Eur. Heart J., 1999, 20, 1253-1260.
48. Weintraub, W.S.; Culler, S.; Boccuzzi, S.J.; Cook, J.R.; Kosinski, A.S.; Cohen, D.J.; Burnette, J. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J. Am. Coll. Cordiol. 1999, 34, 1061-1066.